The ligands of peroxisome proliferator-activated receptor (PPAR) gamma inhibit growth of human esophageal carcinoma cells through induction of apoptosis and cell cycle arrest

Anticancer Research

Volumn 24, Issue 3 A, 2004, Pages 1409-1416

  Fujii, Daisuke ^a   Yoshida, Kazuhiro ^a   Tanabe, Kazuaki ^a   Hihara, Jun ^a   Toge, Tetsuya ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cell cycle regulator; Esophageal cancer; Molecular targeting; PPAR

Indexed keywords

CYCLIN D; CYCLIN E; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; PROTEIN; TROGLITAZONE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; ESOPHAGUS CARCINOMA; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE, TUMOR; CHROMANS; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 3242679874     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Li M, Lotan R, Levin B, Tahara E, Lippman SM and Xu XC: Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention. Cancer Epidemiol Biomark Prevent 9: 545-549, 2000.
2. Foundation for Promotion of Cancer Reseach. Cancer statistics in Japan-2001.
3. McCann J: Esophageal cancers changing character increasing incidence. J Nat Cancer Inst 91: 497-498, 1999.
4. Walczak R and Tontonoz P: PPARadigms and PPARadoxes expanding roles for PPARgamma in the control of lipid metabolism. J Lipid Res 43: 177-186, 2002.
5. Debril MB, Renaud JP, Fajas L and Auwerx J: The pleiotropic functions of peroxisome proliferator-activated receptor gamma. J Mol Med 79: 30-47, 2001.
6. Fajas L, Debril MB and Auwerx J: Peroxisome proliferator-activated receptor-gamma from adipogenesis to carcinogenesis. J Mol Endocrinol 27: 1-9, 2001.
7. Vanden Heuvel JP: Peroxisome proliferator-activated receptors a critical link among fatty acids, gene expression and carcinogenesis. J Nutr 129: 575-580, 1999.
8. Vanden Heuvel JP: Peroxisome proliferator-activated receptors (PPARS) and carcinogenesis. Toxicol Sci 47: 1-8, 1999.
9. Dubuquoy L, Dharancy S, Nutten S, Pettersson S, Auwerx J and Desreumaux P: Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 360: 1410-1418, 2002.
10. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A and Evans RM: PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 4: 585-595, 1999.
11. Ricote M, Li AC, Willson TM, Kelly CJ and Glass CK: The peroxisome proliferator activated receptor gamma is a negative regulator of macrophage activation. Nature 391: 79-82, 1998.
12. Mukherjee R, Jow L, Croston GE and Paterniti JR Jr.: Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPAR gamma2 versus PPAR gamma1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 272: 8071-8076, 1997.
13. Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K, Derijard B, Desvergne B, Wahli W, Chambon P, Leibowitz MD, Colombel JF and Auwerx J: Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer a basis for new therapeutic strategies. J Exp Med 193: 827-838, 2001.
14. Schoonjans K, Staels B and Auwerx J: The peroxisome proliferator activated receptors (PPAR) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302: 93-109, 1996.
15. Desreumaux P, Ernst O, Geboes K, Gambiez L, Berrebi D, Muller-Alouf H, Hafraoui S, Emilie D, Ectors N, Peuchmaur M, Cortot A, Capron M, Auwerx J and Colombel JF: Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 117: 73-81, 1999.
16. Braissant O, Foufelle F, Scotto C, Dauca M and Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs) tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137: 354-366, 1996.
17. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG and Leibowitz MD: Thiazolidinediones produce a conformational change in peroxisome proliferator-activated receptor gamma binding and activation correlate with anti-diabetic actions in db/db mice. Endocrinology 137: 4189-95, 1996.
18. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR and Shulman GI: Metabolic effects of Troglitazone in monotherapy in Type 2 diabetes mellitus. Ann Int Med 128: 176-185, 1998.
19. Debril MB, Renaud JP, Fajas L and Auwerx J: The pleiotropic functions of peroxisome proliferator-activated receptor gamma. J Mol Med 79: 30-47, 2001.
20. Tontonoz P, Graves RA, Budavari AI, Erdjument-Bromage H, Lui M, Hu E, Tempst P and Spiegelman BM: Adipocyte-specific transcription factor ARF 6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma, and RXRa. Nucleic Acid Res 22: 5628-34, 1994.
21. Kodera Y, Takeyama K, Murayama A, Suzawa M, Masuhiro Y and Kato S: Ligand type-sprcific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators. J Biol Chem 275: 33201-4, 2000.
22. Clark RB: The role of PPARs in inflammation and immunity. J Leukoc Biol 71: 388-400, 2002.
23. Ji JD, Cheon H, Jun JB, Choi SJ, Kim YR, Lee YH, Kim TH, Chae IJ, Song GG, Yoo DH, Kim SY and Sohn J: Effects of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) on the expression of inflammatory cytokines and apoptosis induction in rheumatoid synovial fibroblasts and monocytes. J Autoimmun 17: 215-221, 2001.
24. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, Libby P, Plutzky J and Luster AD: Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 164: 6503-6508, 2000.
25. Hsueh WA and Law RE: PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 21: 1891-1895, 2001.
26. Fruchart JC, Staels B and Duriez P: PPARS, metabolic disease and atherosclerosis. Pharmacol Res 44: 345-352, 2001.
27. Yoshida K, Tanabe K, Fujii D, Oue N, Yasui W and Toge T: Induction mechanism of apoptosis by Troglitazone through peroxisome proliferator-activated receptor gamma in gastric carcinoma cells. Anticancer Res 23: 267-274, 2003.
28. Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata Y and Yutaka K: Activation of PPAR gamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Letters 455: 135-139, 1999.
29. Wanlin Y and Harold F: Activation of PPAR pathway induces apoptosis and COX2 inhibition HT-29 human colon cancer cells. Carcinogenessis 22: 1379-1383, 2001.
30. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C and Spiegelman BM: Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Natur Medicine 4: 1046-1052, 1998.
31. Tanaka T, Kohno H, Yoshitani S, Takashima S, Okumura A, Murakami A and Hosokawa M: Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt. Cancer Res 61: 2424-2428, 2001.
32. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM and Spiegelman BM: Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc Natl Acad Sci 94: 237-241, 1997.
33. Hirase N, Yanase T, Mu Y, Muta K, Umemura T, Takayanagi R and Nawata H: Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60. Oncology 57: 17-26, 1999.
34. Yoshizawa K, Cioca DP, Kawa S, Tanaka E and Kiyosawa K: Peroxisome proliferator-activated receptor γ ligand Troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. Cancer 95: 2243-2251, 2002.
35. Motomura W, Okumura T, Takahashi N, Obara T and Kohgo Y: Activation of peroxisome proliferator-activated receptor γ by Troglitazone inhibits cell growth the increase of P27Kip1 in human pancreatic carcinoma cells. Cancer Res 60: 5558-5564, 2000.
36. Rubin GL, Zhao Y, Kalus AM and Simpson ER: Peroxisome proliferator-activated receptor γ ligands inhibit estrogen biosynthesis in human breast adipose tissue:possible implications for breast cancer therapy. Cancer Res 60: 1604-1608, 2000.
37. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D and Koeffler HP: Ligand for peroxisome proliferator- activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and BNX mice. Proc Natl Acad Sci USA 95: 8806-8811, 1998.
38. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I and Koeffler HP: Ligand for peroxisome proliferator-activated receptor γ (Troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58: 3344-3352, 1998.
39. Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S and Koeffier HP: Down regulation of prostate specific antigen expression by ligands for peroxisome proliferator-activated receptor γ in human prostate cancer. Cancer Res 60: 5494-5498, 2000.
40. Yoshida K, Kawami H, Yamaguchi Y, Kuniyasu H, Nishiyama M, Hirai T, Yanagihara K, Tahara E and Toge T: Retrovirally transmitted gene therapy for gastric carcinoma using herpes simplex virus thymidine kinase gene. Cancer 75: 1467-71, 1995.
41. Green DR and Reed JC: Mitochondria and apoptosis. Science 281: 1309-1312, 1998.
42. Nagata S: Apoptosis by death factor. Cell 88: 355-365, 1997.
43. Kennedy SG, Kandel ES, Cross TK and Hay N: AKT/protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol 19: 5800-5810, 1999.
44. Li H, Zhu H, Xu CJ and Yuan J: Cleavage of BID by caspase-8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501, 1998.
45. Khwaja A: Akt is more than just a Bad kinase. Nature 401: 33-34, 1999.
46. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM and Halperin JA: Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 61: 6213-8, 2001.
47. Takashima T, Fujiwara Y, Higuchi K, Arakawa T, Yano Y, Hasuma T and Otani S: PPAR gamma ligands inhibit growth of human esophageal carcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarbolase activity. Int J Onc 19: 465-471, 2001.
48. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB and Korsmeyer SJ: BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 292: 727-730, 2001.
49. Lassus P, Opitz-Araya X and Lazebnik Y: Requirement for Caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 297: 1352-1354, 2002.
50. Lucarelli E, Sangiorgi L, Maini V, Lattanzi G, Marmiroli S, Reggiani M, Mordenti M, Alessandra Gobbi G, Scrimieri F, Zambon Bertoja A and Picci P: Troglitazione affects survival of human osteosarcoma. Int J Cancer 98: 344-51, 2002.
51. Fehlberg S, Trautwein S, Goke A and Goke R: Bisphenol a diglycidyl ether induces apoptosis in tumor cells independently of peroxisome proliferator-activated receptor γ in caspase-dependent and -independent manners. Biochem J 362: 573-578, 2002.
52. Inoue H, Tanabe T and Umesono K: Feedback control of cyclooxygenase-2 expression through PPARgamma. J Biol Chem 275: 28028-32, 2000.
53. Li MY, Deng H, Zhao JM, Dai D and Tan XY: PPARgamma pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells. World J Gastroenterol 9: 1220-1226, 2003.